Role of the GH-IGF1 system in progression of cancer

[1]  R. Berger,et al.  Proteomic analysis of combined IGF1 receptor targeted therapy and chemotherapy identifies signatures associated with survival in breast cancer patients , 2020, Oncotarget.

[2]  T. Key,et al.  Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Chris Jones,et al.  Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma , 2019, British Journal of Cancer.

[4]  C. Boguszewski,et al.  From dwarves to giants: South American's contribution to the history of growth hormone and related disorders. , 2019, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[5]  H. Werner,et al.  Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy , 2019, Expert opinion on investigational drugs.

[6]  J. Kopchick,et al.  The effects of growth hormone on therapy resistance in cancer , 2019, Cancer drug resistance.

[7]  H. Werner,et al.  Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer , 2019, Oncotarget.

[8]  S. Cianfarani.  Risk of cancer in patients treated with recombinant human growth hormone in childhood , 2019, Annals of pediatric endocrinology & metabolism.

[9]  C. Boguszewski,et al.  Growth Hormone's Links to Cancer. , 2018, Endocrine reviews.

[10]  M. Fleseriu,et al.  Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. , 2018, Endocrine reviews.

[11]  O. Larsson,et al.  Characterization of an activating R1353H insulin-like growth factor 1 receptor variant in a male with extreme tall height. , 2018, European journal of endocrinology.

[12]  P. Chanson,et al.  A Consensus Statement on acromegaly therapeutic outcomes , 2018, Nature Reviews Endocrinology.

[13]  J. Coste,et al.  Increased risk of bone tumors after growth hormone treatment in childhood: A population‐based cohort study in France , 2018, Cancer medicine.

[14]  W. Kiess,et al.  Long‐term safety of growth hormone—A combined registry analysis , 2018, Clinical endocrinology.

[15]  H. Werner,et al.  Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway , 2018, Molecular Cancer.

[16]  J. Kopchick,et al.  MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects? , 2018, European journal of endocrinology.

[17]  A. Brooks,et al.  The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects , 2018, Front. Endocrinol..

[18]  D. Gurwitz,et al.  Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action , 2018, Proceedings of the National Academy of Sciences.

[19]  H. Werner,et al.  Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence. , 2017, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[20]  H. Werner,et al.  Genome-wide profiling of congenital insulin-like growth factor-1 deficient patients: translational implications in cancer prevention and metabolism , 2017 .

[21]  R. Berger,et al.  Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer , 2017, Front. Endocrinol..

[22]  T. Zhu,et al.  Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression , 2017, International journal of molecular sciences.

[23]  R. Salvatori,et al.  MECHANISMS IN ENDOCRINOLOGY: The multiple facets of GHRH/GH/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. , 2017, European journal of endocrinology.

[24]  H. Werner,et al.  IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome. , 2017, Mutation research. Reviews in mutation research.

[25]  S. Smaniotto,et al.  Growth hormone modulates in vitro endothelial cell migration and formation of capillary‐like structures , 2017, Cell biology international.

[26]  Shiyong Wu,et al.  Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps , 2017, Hormones and Cancer.

[27]  A. Tirosh,et al.  Complications of acromegaly: thyroid and colon , 2017, Pituitary.

[28]  C. Boguszewski,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited. , 2016, European journal of endocrinology.

[29]  H. Werner,et al.  Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways , 2016, Front. Oncol..

[30]  D. Gurwitz,et al.  Identification of signaling pathways associated with cancer protection in Laron syndrome. , 2016, Endocrine-related cancer.

[31]  C. Rudin,et al.  Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[32]  L. Bach.  Insulin-Like Growth Factor Binding Proteins--an Update. , 2015, Pediatric endocrinology reviews : PER.

[33]  D. Yee,et al.  Minireview: Were the IGF Signaling Inhibitors All Bad? , 2015, Molecular endocrinology.

[34]  T. Dawson,et al.  Growth hormone and cancer: GH production and action in glioma? , 2015, General and comparative endocrinology.

[35]  G. Johannsson,et al.  Reviewing the safety of GH replacement therapy in adults. , 2015, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[36]  L. Moilanen,et al.  Mortality in acromegaly: a 20-year follow-up study. , 2015, Endocrine-related cancer.

[37]  C. Sklar,et al.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. , 2015, The Journal of clinical endocrinology and metabolism.

[38]  R. Subramani,et al.  Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma , 2014, Experimental & Molecular Medicine.

[39]  H. Werner,et al.  Transcriptional and epigenetic control of IGF1R gene expression: implications in metabolism and cancer. , 2014, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[40]  Xiao-yu Wu,et al.  Growth hormone protects colorectal cancer cells from radiation by improving the ability of DNA damage repair. , 2014, Molecular medicine reports.

[41]  H. Werner,et al.  The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches , 2014, Front. Endocrinol..

[42]  L. Attardi,et al.  Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.

[43]  G. Armstrong,et al.  Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. , 2014, The Journal of clinical endocrinology and metabolism.

[44]  Shin-ichiro Takahashi,et al.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation , 2013, Cellular and Molecular Life Sciences.

[45]  J. Kopchick,et al.  Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment. , 2013, Biochemical and biophysical research communications.

[46]  S. Melmed,et al.  Growth hormone is a cellular senescence target in pituitary and nonpituitary cells , 2013, Proceedings of the National Academy of Sciences.

[47]  R. Baserga.  The decline and fall of the IGF‐I receptor , 2013, Journal of cellular physiology.

[48]  V. Rotter,et al.  p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity , 2013, Cell Death and Differentiation.

[49]  H. Werner,et al.  IGF-1 and BRCA1 signalling pathways in familial cancer. , 2012, The Lancet. Oncology.

[50]  T. Zhu,et al.  Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. , 2012, Endocrine-related cancer.

[51]  H. Werner.  Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer , 2012, Oncogene.

[52]  H. Schayek,et al.  BRCA1 is Expressed in Uterine Serous Carcinoma (USC) and Controls Insulin-Like Growth Factor I Receptor (IGF-IR) Gene Expression in USC Cell Lines , 2012, International Journal of Gynecologic Cancer.

[53]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[54]  S. Malozowski.  Reports of increased mortality and GH: will this affect current clinical practice? , 2012, The Journal of clinical endocrinology and metabolism.

[55]  J. Coste,et al.  Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. , 2012, The Journal of clinical endocrinology and metabolism.

[56]  J. Baselga,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[57]  Z. Laron,et al.  Growth hormone therapy: emerging dilemmas. , 2011, Pediatric endocrinology reviews : PER.

[58]  Z. Laron,et al.  Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. , 2011, European journal of endocrinology.

[59]  Federica Madia,et al.  Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans , 2011, Science Translational Medicine.

[60]  M. Oren,et al.  New plays in the p53 theater. , 2011, Current opinion in genetics & development.

[61]  M. Waters,et al.  Role of the growth hormone–IGF-1 axis in cancer , 2011, Expert review of endocrinology & metabolism.

[62]  H. Schayek,et al.  Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells , 2010, Molecular and Cellular Endocrinology.

[63]  J. Spicer,et al.  The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study , 2010, British Journal of Cancer.

[64]  R. Radinsky,et al.  AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells , 2009, Molecular Cancer Therapeutics Molecular Cancer Therapeutics.

[65]  C. Print,et al.  Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. , 2009, Endocrinology.

[66]  M. Pollak,et al.  The Type 1 Insulin-Like Growth Factor Receptor Pathway , 2008, Clinical Cancer Research.

[67]  D. Johnston,et al.  Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. , 2008, The American journal of pathology.

[68]  M. Mitchell,et al.  Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. , 2008, Endocrinology.

[69]  P. Picci,et al.  Targeting insulin-like growth factor 1 receptor in sarcomas , 2008, Current opinion in oncology.

[70]  D. Leroith,et al.  Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. , 2008, Cancer research.

[71]  J. Attems,et al.  Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. , 2007, Endocrine-related cancer.

[72]  I. Holdaway.  Excess Mortality in Acromegaly , 2007, Hormone Research in Paediatrics.

[73]  Xiao-yu Wu,et al.  Growth hormone receptor expression is up-regulated during tumorigenesis of human colorectal cancer. , 2007, The Journal of surgical research.

[74]  R. Yarden,et al.  Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. , 2007, Cancer letters.

[75]  M. Waters,et al.  Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis , 2007, Proceedings of the National Academy of Sciences.

[76]  R. Yarden,et al.  Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[77]  C. Ingvar,et al.  Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women , 2007, British Journal of Cancer.

[78]  Z. Laron,et al.  Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. , 2007, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[79]  S. Melmed.  Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[80]  Adrian V. Lee,et al.  Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. , 2006, The Journal of endocrinology.

[81]  X. Coumoul,et al.  Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. , 2006, Cancer research.

[82]  H. Werner,et al.  Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer , 2006, Molecular and Cellular Endocrinology.

[83]  F Berrino,et al.  IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). , 2006, Endocrine-related cancer.

[84]  V. Ray,et al.  Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. , 2005, Endocrinology.

[85]  H. Werner,et al.  The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[86]  M. Waters,et al.  The oncogenic potential of autocrine human growth hormone in breast cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[87]  C. Sklar.  Growth Hormone Treatment: Cancer Risk , 2004, Hormone Research in Paediatrics.

[88]  R. Shi,et al.  IGF‐I and breast cancer: A meta‐analysis , 2004, International journal of cancer.

[89]  E. Weiss-Messer,et al.  Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells , 2004, Molecular and Cellular Endocrinology.

[90]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[91]  M. Armoni,et al.  The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.

[92]  Z. Laron,et al.  Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. , 2004, The Journal of clinical endocrinology and metabolism.

[93]  C. Lautier,et al.  IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. , 2003, The New England journal of medicine.

[94]  H. Werner,et al.  Functional and Physical Interactions between BRCA1 and p53 in Transcriptional Regulation of the IGF-IR Gene , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[95]  T. Ouchi,et al.  BRCA1–Sp1 interactions in transcriptional regulation of the IGF‐IR gene , 2003, FEBS letters.

[96]  H. Werner,et al.  WT1-p53 Interactions in Insulin-like Growth Factor-I Receptor Gene Regulation* , 2003, The Journal of Biological Chemistry.

[97]  J. Olsen,et al.  Acromegaly and cancer risk: a cohort study in Sweden and Denmark , 2002, Cancer Causes & Control.

[98]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[99]  R. Shi,et al.  Insulin-like growth factor-I and prostate cancer: a meta-analysis , 2001, British Journal of Cancer.

[100]  L. Kindblom,et al.  Growth hormone receptor is expressed in human breast cancer. , 2001, The American journal of pathology.

[101]  R. Fishel,et al.  BRCA1 and cell signaling , 2000, Oncogene.

[102]  A. Benner,et al.  Down‐regulation of insulin‐like growth factor‐I receptor and insulin receptor substrate‐1 expression in advanced human breast cancer , 2000, International journal of cancer.

[103]  G. Nilsson,et al.  Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. , 2000, Cancer research.

[104]  W. Willett,et al.  A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[105]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[106]  M. Lippman,et al.  BRCA1 and BRCA2 in breast cancer , 1999, Breast Cancer Research and Treatment.

[107]  C. Mantzoros,et al.  Leptin in relation to carcinoma In situ of the breast: A study of pre‐menopausal cases and controls , 1999, International journal of cancer.

[108]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[109]  D. Germani,et al.  In vitro effects of growth hormone (GH) and insulin‐like growth factor I and II (IGF‐I and ‐II) on chromosome fragility and p53 protein expression in human lymphocytes , 1998, European journal of clinical investigation.

[110]  R. Baserga,et al.  The IGF-I receptor and cancer , 1997, Endocrine.

[111]  D. Graves,et al.  Risk of leukemia in children treated with human growth hormone: review and reanalysis. , 1997, The Journal of pediatrics.

[112]  I. Lerer,et al.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. , 1997, American journal of human genetics.

[113]  R. Baserga,et al.  The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal , 1997, Molecular and cellular biology.

[114]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[115]  K. Siddle,et al.  c phosphorylation and activation of the IGF-I receptor in src-transformed cells. , 1994, The Journal of biological chemistry.

[116]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[117]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[118]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[119]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[120]  M. Rubini,et al.  Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[121]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[122]  M. Oren.  p53: the ultimate tumor suppressor gene? , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[123]  N. Stahnke.  Leukemia in growth-hormone-treated patients: an update, 1992. , 1992, Hormone research.

[124]  A. Ferber,et al.  The protooncogene c-myb increases the expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor messenger RNAs by a transcriptional mechanism. , 1991, Cancer research.

[125]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[126]  H. Werner,et al.  Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. , 1990, Molecular endocrinology.

[127]  G. Novelli,et al.  Laron dwarfism and mutations of the growth hormone-receptor gene. , 1989, The New England journal of medicine.

[128]  L. Meacham,et al.  Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[129]  A. Pertzelan,et al.  Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism? , 1966, Israel journal of medical sciences.

[130]  H. Werner,et al.  Fifty years on: New lessons from Laron syndrome. , 2017, The Israel Medical Association journal : IMAJ.

[131]  H. Werner,et al.  p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. , 2012, European journal of cancer.

[132]  K. Parker,et al.  Long-term safety of recombinant human growth hormone in children. , 2010, The Journal of clinical endocrinology and metabolism.

[133]  H. Werner.  The Pathophysiological Significance of IGF-I Receptor Overexpression: New Insights , 2009 .

[134]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[135]  B. Ray,et al.  Results of hypophysectomy in the treatment of metastatic mammary carcinoma , 1959, Cancer.